Shadan has held numerous leadership positions at medtech firms, including Zimmer Biomet (NYSE:ZBH), Covidien, Bristol Myers Squibb and Merck, Westborough, Mass.-based Miach said. Prior to joining Miach, Shadan lead rotator cup repair device firm Rotation Medical, which was acquired by Smith & Nephew for $210 million in December 2017.
Shadan has also served as exec chairwoman of Miach’s board of directors since September last year, the company said. She also serves on AdvaMed’s board of directors, and serves as board chair of the Accel Board of Directors and is a founding member of the Leadership Circle for the Women’s Executive Network.
“We are very glad to have Martha Shadan joining the Miach team. Her experience in the medical device space with successful commercialization of medical devices brings in a very valuable skill set, and we are very much looking forward to working with her as the CEO,” founder & chief medical officer Dr. Martha Murray said in a press release.
NuVasive (NSDQ:NUVA) said today that its new CEO and former Medtronic (NYSE:MDT) surgical innovations prez Chris Barry has made significant organizational changes to its executive leadership roster as the company looks to improve internal growth and drive innovation.
The San Diego-based company said that its current prez Matt Link will retain his position with expanded responsibilities, including the direct management of its clinical services and global logistics businesses.
Current CFO and exec VP Raj Asarpota will retain their role alongside new responsibilities leading the company’s finance, accounting, internal audit and tax teams, the company said, while GC and corporate secretary Nate Sisitsky will continue in their role, but will also oversee the company’s real estate and facilities.
Chief compliance officer Jim Garrett will assume an expanded role overseeing the company’s business and quality systems functions, which includes GRI, regulatory affairs and quality affairs, information technology and environmental health and safety, NuVasive said.
Former HR VP Lucas Vitale was named chief human resources officer, while internal and external affairs lead Suzanne Hatcher and manufacturing head Dale Wolf will retain their positions, the company said.
The positions of global process transformation and people and culture exec VP, held by Stephen Rozow and Pete Leddy, respevtively, have been eliminated, NuVasive said.
“After assessing the company over the past two months as CEO, it is clear that NuVasive benefits from significant talent across the organization. Our new structure will enable us to better capitalize on this talent by fostering cross-functional collaboration, consolidating complementary functions and increasing accountability. I am confident this leadership team and our new structure, along with disciplined execution, will better position NuVasive to fulfill our commitments to patients, surgeons, employees and shareholders, and drive NuVasive’s success and sustainable growth,” Barry said in a press release.
Obalon Therapeutics (NSDQ:OBLN) said yesterday that it promoted former prez & chief operating officer Kelly Huang to the position of chief executive officer, with former CEO Andy Rasdal taking up the position of exec chair.
Prior to joining Obalon, Huang served as GM for Galderma Laboratories’ aesthetic & corrective division. Before taking the position with Galderma, Huang acted as prez of Endo Pharmaceutical’s exec committee, San Diego-based Obalon said.
“More than a year ago, we brought Kelly in as chief operating officer to lead commercial operations. Kelly has continued to demonstrate that he is a strong and capable leader, and we believe he will be effective as CEO of Obalon. I intend to stay actively involved as executive chairman, primarily to serve as a resource to Kelly, and will also focus on several key strategic projects to help build the intragastric balloon market and create sustainable value for Obalon,” Rasdal said in a press release.
The company also announced that it promoted its clinical and regulatory affairs VP Amy Vandenberg to the position of chief clinical and regulatory affairs officer. Prior to joining Obalon, she held positions at companies including Dexcom and Cygnus.
“Amy led the clinical and regulatory aspects for FDA approval of Obalon’s original PMA and recent PMA-S approval of the Navigation/Touch system. She continues to lead across all functions and levels of the organization. I am pleased to recognize Amy’s contributions to the current business and future pipeline with her promotion to chief clinical & regulatory affairs officer,” CEO Huang said in a separate release.
Lightmed said yesterday that it reappointed its founder and exec chair Gary Lee as its new CEO, replacing Shlomo Alkalay who will return to a consultancy position.
In addition to the appointment, the San Clemente, Calif.-based company said that biz dev director Jennifer Lee was appointed to GM of Americas, effective immediately.
“I am proud to say that during my 1.5 years as CEO of Lightmed, the company has successfully accomplished implementation of our turn-around plan. Lightmed is now much better equipped with best-of-breed automated processes, controls and KPIs to face future global challenges and meaningful growth. I’ve completed what I set out to do and feel confident the company is not only in great shape, but I’m leaving it in the strongest hands under the original leadership of the company founder, Gary Lee,” Alkalay said in a prepared statement.
“Shlomo has shown exceptional leadership and has strategically guided Lightmed to a better position. Speaking on behalf of the entire board, we very much appreciate Shlomo’s service to Lightmed and he will be missed. Shlomo joined as CEO just at the right time when I needed to focus my efforts on our venture capital strategy. Now that the company is healthier and running smoothly, I’m looking forward to taking Lightmed to the next level of expanded product innovation and growth. Furthermore, I’m excited that our director of business development, Jennifer Lee, has assumed her new role in managing the USA, Latin America and Canada. Jennifer is an excellent leader and communicator who has shown remarkable capabilities in building new and existing business relationships. I look forward to seeing her grow our western market in 2019,” Lee said in a prepared release.
Nobilis Health said late last month that it appointed James Springfield as its new CEO.
Prior to joining Houston-based Nobilis, Springfield held positions with Memorial Hermann Health Care System, and served in leadership positions at a number of different hospitals and health systems.
“I am excited to take on this role and opportunity, as I have followed the Nobilis story in the Texas market and have seen their dramatic shift in-network and how the management team has successfully grown its medical facility infrastructure (including clinics, ambulatory surgery centers, and hospitals) as well its unique direct to consumer marketing platform. This proprietary marketing technology provides Nobilis with the unique ability to quickly add new products and specialties and in combination with the recent significant increase of the company’s in-network business, makes Nobilis poised for strong and sustainable growth. The scalability of the marketing platform allows Nobilis to enter new markets with ease and certainty. With the significant expansion of the company’s in-network business, there is now an opportunity to recruit from a much larger base of physicians, especially in the Texas market. The company intends to pursue alignment with physicians in new and existing specialties, while expanding the Nobilis brands to include total joint replacements, ENT and cardiovascular services, among others. This is a vision and strategy that the management team and the company’s board of directors share. As Nobilis’ CEO, I welcome the responsibility of executing on this vision, and look forward to achieving the results I believe shareholders want to see. Nobilis will be the only in-network healthcare system that can use marketing to address both patient and provider needs. In the coming months I look forward to sharing a clear plan on maximizing shareholder value for Nobilis investors,” Springfield said in a press release.
“Jim has extensive executive leadership experience with several of the nation’s largest healthcare providers and payors which fits in well with Nobilis’ shift to an in-network system. The addition of Jim Springfield to the Nobilis team as CEO will allow us to execute and achieve the benefits of an in-network model, including faster collection cycle, larger addressable market, certainty in revenue recognition, and greater willingness from physicians to participate in the in-network space, among other key advantages. He has led out of network to in-network conversions and is ideally suited to finalize Nobilis’ migration to being an in-network healthcare provider,” board chair Harry Fleming said in a prepared statement.